Regeneron Pharmaceuticals
REGN
658 hedge funds and large institutions have $23.1B invested in Regeneron Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 64 funds opening new positions, 243 increasing their positions, 258 reducing their positions, and 111 closing their positions.
0.24% less ownership
Funds ownership: 68.95% → 68.71% (-0.24%)
6% less repeat investments, than reductions
Existing positions increased: 243 | Existing positions reduced: 258
8% less funds holding
Funds holding: 718 → 658 (-60)
22% less call options, than puts
Call options by funds: $507M | Put options by funds: $646M
24% less capital invested
Capital invested by funds: $30.4B → $23.1B (-$7.27B)
42% less first-time investments, than exits
New positions opened: 64 | Existing positions closed: 111
55% less funds holding in top 10
Funds holding in top 10: 11 → 5 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Harris Associates
Chicago,
Illinois
|
+$415M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$202M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$161M |
| 4 |
Parnassus Investments
San Francisco,
California
|
+$155M |
| 5 |
Millennium Management
New York
|
+$146M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$409M |
| 2 |
Sands Capital Management
Arlington,
Virginia
|
-$338M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$317M |
| 4 |
JP Morgan Chase
New York
|
-$247M |
| 5 |
DCP
DSM Capital Partners
Palm Beach Gardens,
Florida
|
-$154M |
REGN Hedge Fund Activity: Q2 2019 in Review
658 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q2 2019, worth a combined $23.1B — down 24% from $30.4B a quarter earlier.
Sellers outnumbered buyers: 111 funds closed out of REGN and 64 opened new positions — a net loss of 47 holders — while 258 trimmed existing stakes and 243 added.
The largest buyer was Harris Associates, adding an estimated $415M. The largest seller was Fidelity Investments, cutting an estimated $409M.
- 658 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q2 2019, down from 718 in Q1 2019.
- Funds reported $23.1B of Regeneron Pharmaceuticals stock for Q2 2019, down 24% quarter-over-quarter.
- 64 funds opened new Regeneron Pharmaceuticals positions in Q2 2019 and 111 closed out, a net change of -47 holders.
- The largest Regeneron Pharmaceuticals buyer in Q2 2019 was Harris Associates, an estimated $415M added.
- The largest Regeneron Pharmaceuticals seller in Q2 2019 was Fidelity Investments, an estimated $409M sold.
Based on aggregated 13F filings for Q2 2019.